Abstract
Globally, the burden of cancer is substantial and growing. The impact of the burden of such diseases over society is unpredictable in terms of health lost and cost. Unfortunately, the estimates shown the burden may be increasing in the upcoming decades. Cabozantinib (CBZ) is a newly developed tyrosin kinase inhibitor (TKI) for Differentiated thyroid cancer (DTC), Hepatic Cellular Carcinoma (HCC), Medullary thyroid cancer (MTC) and Renal Cell Carcinoma (RCC). The objective of the presented review is to provide updated knowledge of drugs especially covering analytical methodologies. The review covered the introduction, mechanism of action, pharmacokinetics, synthesis and developed analytical methods by various researchers. The review covered one spectrophotometry and about twenty chromatography methods. The review will be helpful for the scientist working in this area and especially helpful for analytical scientists exploring new analytical methodologies for CBZ.
Publisher
Innovare Academic Sciences Pvt Ltd
Reference76 articles.
1. Herbrink M, Nuijen B, Schellens JH, Beijnen JH. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treat Rev. 2015;41(5):412-22. doi: 10.1016/j.ctrv.2015.03.005. PMID 25818541.
2. Cancer. World Health Organization; 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer#:~:text=The%20problem-,Cancer%20is%20a%20leading%20cause%20of%20death%20worldwide%2C%20accounting%20for,lung%20(2.21%20million%20cases)%3B. [Last accessed on 09 Sep 2022]
3. Hausman DM. What is cancer? Perspect Biol Med. 2019;62(4):778-84. doi: 10.1353/pbm.2019.0046, PMID 31761807.
4. Roy PS, Saikia BJ. Cancer and cure: A critical analysis. Indian J Cancer. 2016 Jul-Sep;53(3):441-2. doi: 10.4103/0019-509X.200658, PMID 28244479.
5. National Cancer Institute at the National Institutes of Health; 2020. Available from: https://www.cancer.gov/about-cancer/understanding. [Last accessed on 27 Jun 2022]